来凯医药-B(02105.HK)：LAE103的I期单剂量递增研究完成首例受试者给药

Group 1 - The company, Lai Kai Pharmaceutical-B (02105.HK), has initiated the enrollment of subjects for the Phase I single ascending dose (SAD) study of LAE103, a self-developed ActRIIB monoclonal antibody, in Australia [1] - The SAD study is a randomized, double-blind, placebo-controlled trial aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE103 (subcutaneous injection) in healthy overweight or obese subjects [1] - The company aims to announce the top-line data from this SAD study in the third quarter of 2026, focusing on introducing this precision therapy into areas with significant unmet medical needs in cardiovascular and metabolic diseases, such as obesity, sarcopenia, and heart failure [1]